Identification and Root Cause Analysis of the Visible Particles Commonly Encountered in the Biopharmaceutical Industry

References

1. 1.↵
   1. Cromwell M. E. M.,
   2. Hilario E.,
   3. Jacobson F.

   Protein Aggregation and Bioprocessing. AAPS J. 2006, 8 (3), E572–E579.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   1. Das T. K.

   Protein Particulate Detection Issues in Biotherapeutics Development—Current Status. AAPS PharmSciTech 2012, 13 (2), 732–746.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Doessegger L.,
   2. Mahler H.-C.,
   3. Szczesny P.,
   4. Rockstroh H.,
   5. Kallmeyer G.,
   6. Langenkamp A.,
   7. Herrmann J.,
   8. Famulare J.

   The Potential Clinical Relevance of Visible Particles in Parenteral Drugs. J. Pharm. Sci. 2012, 101 (8), 2635–2644.

   OpenUrlPubMed
4. 4.↵
   1. Mahler H.-C.,
   2. Friess W.,
   3. Grauschopf U.,
   4. Kiese S.

   Protein Aggregation: Pathways, Induction Factors and Analysis. J. Pharm. Sci. 2009, 98 (9), 2909–2934.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Mathonet S.,
   2. Mahler H.-C.,
   3. Esswein S. T.,
   4. Mazaheri M.,
   5. Cash P. W.,
   6. Wuchner K.,
   7. Kallmeyer G.,
   8. Das T. K.,
   9. Finkler C.,
   10. Lennard A.

   A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2016, 70 (4), 392–408.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Bukofzer S.,
   2. Ayres J.,
   3. Chavez A.,
   4. Devera M.,
   5. Miller J.,
   6. Ross D.,
   7. Shabushnig J.,
   8. Vargo S.,
   9. Watson H.,
   10. Watson R.

   Industry Perspective on the Medical Risk of Visible Particles in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2015, 69 (1), 123–139.

   OpenUrlFREE Full Text
7. 7.↵
   1. Cao X.,
   2. Masatani P.,
   3. Torraca G.,
   4. Wen Z.-Q.

   Identification of a Mixed Microparticle by Combined Microspectroscopic Techniques: A Real Forensic Case Study in the Biopharmaceutical Industry. Appl. Spectrosc. 2010, 64 (8), 895–900.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Anger S.,
   2. Begat C.,
   3. Crnko V.,
   4. Fantozzi G.,
   5. Farach W.,
   6. Fitzpatrick S.,
   7. Gallagher B.,
   8. Huelsmann S.,
   9. Kinsey P.,
   10. Langlade V.,
   11. Lefevre G.,
   12. Legendre E.,
   13. McLean K.,
   14. Miller J.,
   15. Patel R.,
   16. Perry A.,
   17. Soukiassian H.,
   18. Stanton A.,
   19. Streich D.,
   20. Timmons C.,
   21. Vaneylen D.,
   22. van Hoose T.,
   23. Wildling L.,
   24. Windover M.

   Points to Consider: Best Practices to Identify Particle Entry Routes Along the Manufacturing Process for Parenteral Formulations. PDA J. Pharm. Sci. Technol. 2019, 73 (6), 635–647.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   U.S. Pharmacopeial Convention. General Chapter <1787> Measurement of Subvisible Particulate Matter in Therapeutic Protein Injections. In USP 43—NF 38, USP: Rockville, MD, 2021.
10. 10.↵
    1. Cao X.,
    2. Stimpfl G.,
    3. Wen Z.-Q.,
    4. Frank G.,
    5. Hunter G.

    Identification and Root Cause Analysis of Cell Culture Media Precipitates in the Viral Deactivation Treatment with High-Temperature/Short-Time Method. PDA J. Pharm. Sci. Technol. 2013, 67 (1), 63–73.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Hindelang F.,
    2. Roggo Y.,
    3. Zurbach R.

    Forensic Investigation in the Pharmaceutical Industry: Identification Procedure of Visible Particles in (Drug) Solutions and Different Containers by Combining Vibrational and X-Ray Spectroscopic Techniques. J. Pharm. Biomed. Anal. 2018, 148 334–349.

    OpenUrlPubMed
12. 12.↵
    1. Causin V.,
    2. Marega C.,
    3. Guzzini G.,
    4. Marigo A.

    Forensic Analysis of Poly(Ethylene Terephthalate) Fibers by Infrared Spectroscopy. Appl. Spectrosc. 2004, 58 (11), 1272–1276.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Cao X.,
    2. Wen Z.-Q.,
    3. Vance A.,
    4. Torraca G.

    Raman Microscopic Applications in the Biopharmaceutical Industry: In Situ Identification of Foreign Particulates inside Glass Containers with Aqueous Formulated Solutions. Appl. Spectrosc. 2009, 63 (7), 830–834.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Cao X.,
    2. Loussaert J. A.,
    3. Wen Z-Q.

    Microspectroscopic Investigation of the Membrane Clogging During the Sterile Filtration of the Growth Media for Mammalian Cell Culture. J. Pharm. Biomed. Anal. 2016, 119 10–15.

    OpenUrlPubMed
15. 15.↵
    1. Jameel F.,
    2. Skoug J. W.,
    3. Nesbitt R. R.

    1. Messick S.,
    2. Saggu M.,
    3. Ríos Quiroz A.

    Chapter 11: Particles in Biopharmaceuticals: Causes, Characterization, and Strategy. In Development of Biopharmaceutical Drug-Device Products, Jameel F., Skoug J. W., Nesbitt R. R., Eds.; AAPS Advances in the Pharmaceutical Sciences Series, Vol 35; Springer International Publishing: Cham, 2020; pp 251–264.
16. 16.↵
    1. Brown A. E.,
    2. Reinhart K. A.

    Polyester Fiber: From Its Invention to Its Present Position. Science 1971, 173 (3994), 287–293.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Shit S. C.,
    2. Shah P.

    A Review on Silicone Rubber. Natl. Acad. Sci. Lett. 2013, 36 (4), 355–365.

    OpenUrlCrossRef
18. 18.↵
    1. Saller V.,
    2. Matilainen J.,
    3. Grauschopf U.,
    4. Bechtold-Peters K.,
    5. Mahler H.-C.,
    6. Friess W.

    Particle Shedding from Peristaltic Pump Tubing in Biopharmaceutical Drug Product Manufacturing. J. Pharm. Sci. 2015, 104 (4), 1440–1450.

    OpenUrlPubMed
19. 19.↵
    1. Gerhardt A.,
    2. Mcgraw N. R.,
    3. Schwartz D. K.,
    4. Bee J. S.,
    5. Carpenter J. F.,
    6. Randolph T. W.

    Protein Aggregation and Particle Formation in Prefilled Glass Syringes. J. Pharm. Sci. 2014, 103 (6), 1601–1612.

    OpenUrlPubMed
20. 20.↵
    1. Gerhardt A.,
    2. Nguyen B. H.,
    3. Lewus R.,
    4. Carpenter J. F.,
    5. Randolph T. W.

    Effect of the Siliconization Method on Particle Generation in a Monoclonal Antibody Formulation in Pre-Filled Syringes. J. Pharm. Sci. 2015, 104 (5), 1601–1609.

    OpenUrlPubMed
21. 21.↵
    1. Jezek J.,
    2. Darton N. J.,
    3. Derham B. K.,
    4. Royle N.,
    5. Simpson I.

    Biopharmaceutical Formulations for Pre-Filled Delivery Devices. Expert Opin. Drug Delivery 2013, 10 (6), 811–828.

    OpenUrl
22. 22.↵
    1. Gilbert C. R.,
    2. Haouzi P.

    Particle Size, Distribution, and Behavior of Talc Preparations: Within the United States and Beyond. Curr. Opin. Pulm. Med. 2019, 25 (4), 1531–6971.

    OpenUrl
23. 23.↵
    1. Kopp M. R. G.,
    2. Grigolato F.,
    3. Zürcher D.,
    4. Das T. K.,
    5. Chou D.,
    6. Wuchner K.,
    7. Arosio P.

    Surface-Induced Protein Aggregation and Particle Formation in Biologics: Current Understanding of Mechanisms, Detection and Mitigation Strategies. J. Pharm. Sci 2023, 112 (2), 377–385.

    OpenUrlCrossRefPubMed
24. 24.↵
    U.S. Food and Drug Administration, Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. Center for Drug Evaluation and Research, U.S. Department of Health and Human Services: Rockville, MD, 1999.
25. 25.↵
    International Conference for Harmonisation, Quality Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. ICH: Geneva, 2003.
26. 26.↵
    1. Carter S. M.,
    2. Granchelli J.

    Thermo Scientific Nalgene PETG Bottle Performance at −70°C. ThermoFisher Scientific, 2021.
27. 27.↵
    1. Sacha G. A.,
    2. Saffell-Clemmer W.,
    3. Abram K.,
    4. Akers M. J.

    Practical Fundamentals of Glass, Rubber, and Plastic Sterile Packaging Systems. Pharm. Dev. Technol. 2010, 15 (1), 6–34.

    OpenUrlPubMed
28. 28.↵
    U.S. Pharmacopeial Convention. General Chapter <1660> Evaluation of the Inner Surface Durability of Glass Containers. In USP 43—NF 38, USP: Rockville, MD, 2019.
29. 29.↵
    U.S. Pharmacopeial Convention. General Chapter <660> Containers—Glass. In USP 43—NF 38, USP: Rockville, MD, 2019
30. 30.↵
    1. Langille S. E.

    Particulate Matter in Injectable Drug Products. PDA J. Pharm. Sci. Technol. 2013, 67 (3), 186–200.

    OpenUrlAbstract/FREE Full Text
31. 31.↵
    1. Timmons C. L.,
    2. Liu C. Y.,
    3. Merkle S.

    Particulate Generation Mechanisms During Bulk Filling and Mitigation Via New Glass Vial. PDA J. Pharm. Sci. Technol. 2017, 71 (5), 379–392.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Ennis R. D.,
    2. Pritchard R.,
    3. Nakamura C.,
    4. Coulon M.,
    5. Yang T.,
    6. Visor G. C.,
    7. Lee W. A.

    Glass Vials for Small Volume Parenterals: Influence of Drug and Manufacturing Processes on Glass Delamination. Pharm. Dev. Technol. 2001, 6 (3), 393–405.

    OpenUrlPubMed
33. 33.↵
    1. Iacocca R. G.,
    2. Allgeier M.

    Corrosive Attack of Glass by a Pharmaceutical Compound. J. Mater. Sci. 2007, 42 (3), 801–811.

    OpenUrl
34. 34.↵
    1. Schwarzenbach M. S.,
    2. Reimann P.,
    3. Thommen V.,
    4. Hegner M.,
    5. Mumenthaler M.,
    6. Schwob J.,
    7. Güntherodt H.-J.

    Topological Structure and Chemical Composition of Inner Surfaces of Borosilicate Vials. PDA J. Pharm. Sci. Technol. 2004, 58 (3), 169–175.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Ratnaswamy G.,
    2. Hair A.,
    3. Li G.,
    4. Thirumangalathu R.,
    5. Nashed-Samuel Y.,
    6. Brych L.,
    7. Dharmavaram V.,
    8. Wen Z.-Q.,
    9. Fujimori K.,
    10. Jing W.,
    11. Sethuraman A.,
    12. Swift R.,
    13. Ricci M. S.,
    14. Piedmonte D. M.

    A Case Study of Nondelamination Glass Dissolution Resulting in Visible Particles: Implications for Neutral pH Formulations. J. Pharm. Sci. 2014, 103 (4), 1104–1114.

    OpenUrlPubMed
36. 36.↵
    1. Tyagi A. K.,
    2. Banerjee S.

    1. Sengupta P.

    Natural Glasses Under Extreme Conditions. In Materials under Extreme Conditions: Recent Trends and Future Prospects; Tyagi A. K., Banerjee S. Eds.; Elsevier, 2017; pp 235–258.
37. 37.↵
    1. Jones L. S.,
    2. Kaufmann A.,
    3. Middaugh C. R.

    Silicone Oil Induced Aggregation of Proteins. J. Pharm. Sci. 2005, 94 (4), 918–927.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Mizutani T.

    Estimation of Protein and Drug Adsorption onto Silicone-Coated Glass Surfaces. J. Pharm. Sci. 1981, 70 (5), 493–496.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    1. Basu P.,
    2. Krishnan S.,
    3. Thirumangalathu R.,
    4. Randolph T. W.,
    5. Carpenter J. F.

    IgG1 Aggregation and Particle Formation Induced by Silicone-Water Interfaces on Siliconized Borosilicate Glass Beads: A Model for Siliconized Primary Containers. J. Pharm. Sci. 2013, 102 (3), 852–865.

    OpenUrlPubMed
40. 40.↵
    1. Kasimbeg P. N. O.,
    2. Cheong F. C.,
    3. Ruffner D. B.,
    4. Blusewicz J. M.,
    5. Philips L. A.

    Holographic Characterization of Protein Aggregates in the Presence of Silicone Oil and Surfactants. J. Pharm. Sci. 2019, 108 (1), 155–161.

    OpenUrlPubMed
41. 41.↵
    1. Lankers M.,
    2. Munhall J.,
    3. Valet O.

    Differentiation between Foreign Particulate Matter and Silicone Oil Induced Protein Aggregation in Drug Solutions by Automated Raman Spectroscopy. Microsc. Microanal. 2008, 14 (S2), 1612–1613.

    OpenUrl
42. 42.↵
    1. Wang W.,
    2. Ignatius A. A.,
    3. Thakkar S. V.

    Impact of Residual Impurities and Contaminants on Protein Stability. J. Pharm. Sci. 2014, 103 (5), 1315–1330.

    OpenUrlPubMed
43. 43.↵
    1. Li J.,
    2. Pinnamaneni S.,
    3. Quan Y.,
    4. Jaiswal A.,
    5. Andersson F. I.,
    6. Zhang X.

    Mechanistic Understanding of Protein-Silicone Oil Interactions. Pharm. Res. 2012, 29 (6), 1689–1697.

    OpenUrlCrossRefPubMed
44. 44.↵
    1. Mathaes R.,
    2. Mahler H.-C.,
    3. Buettiker J.-P.,
    4. Roehl H.,
    5. Lam P.,
    6. Brown H.,
    7. Luemkemann J.,
    8. Adler M.,
    9. Huwyler J.,
    10. Streubel A.,
    11. Mohl S.

    The Pharmaceutical Vial Capping Process: Container Closure Systems, Capping Equipment, Regulatory Framework, and Seal Quality Tests. Eur. J. Pharm. Biopharm. 2016, 99, 54–64.

    OpenUrlPubMed
45. 45.↵
    1. Hecker A.,
    2. Di Maro A.,
    3. Liechti E. F.,
    4. Klenke F. M.

    Avoiding Unconscious Injection of Vial-Derived Rubber Particles During Intra-Articular Drug Administration. Osteoarthritis and Cartilage Open 2021, 3 (2), 100164.

    OpenUrl
46. 46.↵
    1. Rathore N.,
    2. Rajan R. S.

    Current Perspectives on Stability of Protein Drug Products During Formulation, Fill and Finish Operations. Biotechnol. Prog. 2008, 24 (3), 504–514.

    OpenUrlPubMed
47. 47.↵
    1. Wang W.

    Instability, Stabilization, and Formulation of Liquid Protein Pharmaceuticals. Int. J. Pharm. 1999, 185 (2), 129–188.

    OpenUrlCrossRefPubMedWeb of Science
48. 48.↵
    1. Wang W.,
    2. Singh S.,
    3. Zeng D. L.,
    4. King K.,
    5. Nema S.

    Antibody Structure, Instability, and Formulation. J. Pharm. Sci. 2007, 96 (1), 1–26.

    OpenUrlCrossRefPubMed
49. 49.↵
    1. Sharma B.

    Immunogenicity of Therapeutic Proteins. Part 1: Impact of Product Handling. Biotechnol. Adv. 2007, 25 (3), 310–317.

    OpenUrlCrossRefPubMedWeb of Science
50. 50.↵
    1. Sharma B.

    Immunogenicity of Therapeutic Proteins. Part 2: Impact of Container Closures. Biotechnol. Adv. 2007, 25 (3), 318–324.

    OpenUrlCrossRefPubMedWeb of Science
51. 51.↵
    1. Sharma B.

    Immunogenicity of Therapeutic Proteins. Part 3: Impact of Manufacturing Changes. Biotechnol. Adv. 2007, 25 (3), 325–331.

    OpenUrlCrossRefPubMed
52. 52.↵
    1. Thurow H.,
    2. Geisen K.

    Stabilisation of Dissolved Proteins against Denaturation at Hydrophobic Interfaces. Diabetologia 1984, 27 (2), 212–218.

    OpenUrlPubMed
53. 53.↵
    1. Zhou S.,
    2. Schöneich C.,
    3. Singh S. K.

    Biologics Formulation Factors Affecting Metal Leachables from Stainless Steel. AAPS PharmSciTech 2011, 12 (1), 411–421.

    OpenUrlPubMed
54. 54.↵
    1. Chu G. C.,
    2. Chelius D.,
    3. Xiao G.,
    4. Khor H. K.,
    5. Coulibaly S.,
    6. Bondarenko P. V.

    Accumulation of Succinimide in a Recombinant Monoclonal Antibody in Mildly Acidic Buffers under Elevated Temperatures. Pharm. Res. 2007, 24 (6), 1145–1156.

    OpenUrlPubMed
55. 55.↵
    1. Dolník V.

    Capillary Electrophoresis of Proteins 2003–2005. Electrophoresis 2006, 27 (1), 126–141.

    OpenUrlCrossRefPubMedWeb of Science
56. 56.↵
    1. Gadgil H. S.,
    2. Bondarenko P. V.,
    3. Pipes G.,
    4. Rehder D.,
    5. McAuley A.,
    6. Perico N.,
    7. Dillon T.,
    8. Ricci M.,
    9. Treuheit M.

    The LC/MS Analysis of Glycation of IGG Molecules in Sucrose Containing Formulations. J. Pharm. Sci. 2007, 96 (10), 2607–2621.

    OpenUrlCrossRefPubMedWeb of Science
57. 57.↵
    1. Harris R. J.,
    2. Kabakoff B.,
    3. Macchi F. D.,
    4. Shen F. J.,
    5. Kwong M.,
    6. Andya J. D.,
    7. Shire S. J.,
    8. Bjork N.,
    9. Totpal K.,
    10. Chen A. B.

    Identification of Multiple Sources of Charge Heterogeneity in a Recombinant Antibody. J. Chromatogr. B: Biomed. Sci. Appl. 2001, 752 (2), 233–245.

    OpenUrlCrossRefPubMed
58. 58.↵
    1. Leiske D. L.,
    2. Shieh I. C.,
    3. Tse M. L.

    A Method to Measure Protein Unfolding at an Air–Liquid Interface. Langmuir 2016, 32 (39), 9930–9937.

    OpenUrlPubMed
59. 59.↵
    1. Paul A. J.,
    2. Bickel F.,
    3. Röhm M.,
    4. Hospach L.,
    5. Halder B.,
    6. Rettich N.,
    7. Handrick R.,
    8. Herold E. M.,
    9. Kiefer H.,
    10. Hesse F.

    High-Throughput Analysis of Sub-Visible mAb Aggregate Particles Using Automated Fluorescence Microscopy Imaging. Anal. Bioanal. Chem. 2017, 409 (17), 4149–4156.

    OpenUrlPubMed
60. 60.↵
    1. Shieh I. C.,
    2. Patel A. R.

    Predicting the Agitation-Induced Aggregation of Monoclonal Antibodies Using Surface Tensiometry. Mol. Pharmaceutics 2015, 12 (9), 3184–3193.

    OpenUrl
61. 61.↵
    1. Lin G. L.,
    2. Pathak J. A.,
    3. Kim D. H.,
    4. Carlson M.,
    5. Riguero V.,
    6. Kim Y. J.,
    7. Buff J. S.,
    8. Fuller G. G.

    Interfacial Dilatational Deformation Accelerates Particle Formation in Monoclonal Antibody Solutions. Soft Matter 2016, 12 (14), 3293–3302.

    OpenUrlPubMed
62. 62.↵
    1. Zhai J.,
    2. Lee T.-H.,
    3. Small D. H.,
    4. Aguilar M.-I.

    Characterization of Early Stage Intermediates in the Nucleation Phase of Abeta Aggregation. Biochemistry 2012, 51 (6), 1070–1078.

    OpenUrlPubMed
63. 63.↵
    1. Rosenberg A. S.

    Effects of Protein Aggregates: An Immunologic Perspective. AAPS J. 2006, 8 (3), E501–E507.

    OpenUrlCrossRefPubMedWeb of Science
64. 64.↵
    1. Shukla D.,
    2. Schneider C. P.,
    3. Trout B. L.

    Molecular Level Insight into Intra-Solvent Interaction Effects on Protein Stability and Aggregation. Adv. Drug Delivery Rev. 2011, 63 (13), 1074–1085.

    OpenUrlPubMed
65. 65.↵
    1. Wang W.

    Protein Aggregation and Its Inhibition in Biopharmaceutics. Int. J. Pharm. 2005, 289 (1–2), 1–30.

    OpenUrlCrossRefPubMedWeb of Science
66. 66.↵
    1. Wang W.,
    2. Roberts C. J.

    Protein Aggregation – Mechanisms, Detection, and Control. Int. J. Pharm. 2018, 550 (1–2), 251–268.

    OpenUrlPubMed
67. 67.↵
    1. Lins R. D.,
    2. Pereira C. S.,
    3. Hünenberger P. H.

    Trehalose–Protein Interaction in Aqueous Solution. Proteins 2004, 55 (1), 177–186.

    OpenUrlCrossRefPubMed
68. 68.↵
    1. Timasheff S. N.

    Protein-Solvent Preferential Interactions, Protein Hydration, and the Modulation of Biochemical Reactions by Solvent Components. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (15), 9721–9726.

    OpenUrlAbstract/FREE Full Text
69. 69.↵
    1. Warne N. W.,
    2. Mahler H.-C.

    1. Singh S. K.

    Sucrose and Trehalose in Therapeutic Protein Formulations. In Challenges in Protein Product Development, Warne N. W., Mahler H.-C., Eds.; AAPS Advances in the Pharmaceutical Sciences Series, Vol. 38; Springer International Publishing: Cham, 2018; pp 63–95.
70. 70.↵
    1. Wang B.,
    2. Tchessalov S.,
    3. Warne N. W.,
    4. Pikal M. J.

    Impact of Sucrose Level on Storage Stability of Proteins in Freeze-Dried Solids: I. Correlation of Protein–Sugar Interaction with Native Structure Preservation. J. Pharm. Sci. 2009, 98 (9), 3131–3144.

    OpenUrlPubMed
71. 71.↵
    1. Israelachvili J. N.

    Intermolecular and Surface Forces; Elsevier, 2011.
72. 72.↵
    1. Chen C.-H.,
    2. Yao T.,
    3. Zhang Q.,
    4. He Y.-M.,
    5. Xu L.-H.,
    6. Zheng M.,
    7. Zhou G.-R.,
    8. Zhang Y.,
    9. Yang H.-J.,
    10. Zhou P.

    Influence of Trehalose on Human Islet Amyloid Polypeptide Fibrillation and Aggregation. RSC Adv. 2016, 6 (18), 15240–15246.

    OpenUrl
73. 73.↵
    1. Liu L.,
    2. Qi W.,
    3. Schwartz D. K.,
    4. Randolph T. W.,
    5. Carpenter J. F.

    The Effects of Excipients on Protein Aggregation During Agitation: An Interfacial Shear Rheology Study. J. Pharm. Sci. 2013, 102 (8), 2460–2470.

    OpenUrlPubMed
74. 74.↵
    1. Abbas S. A.,
    2. Sharma V. K.,
    3. Patapoff T. W.,
    4. Kalonia D. S.

    Characterization of Antibody-Polyol Interactions by Static Light Scattering: Implications for Physical Stability of Protein Formulations. Int. J. Pharm. 2013, 448 (2), 382–389.

    OpenUrlPubMed
75. 75.↵
    1. Lim J. Y.,
    2. Kim N. A.,
    3. Lim D. G.,
    4. Eun C-y.,
    5. Choi D.,
    6. Jeong S. H.

    Biophysical Stability of hyFc Fusion Protein with Regards to Buffers and Various Excipients. Int. J. Biol. Macromol. 2016, 86, 622–629.

    OpenUrlPubMed
76. 76.↵
    1. Wen L.,
    2. Zheng X.,
    3. Wang X.,
    4. Lan H.,
    5. Yin Z.

    Bilateral Effects of Excipients on Protein Stability: Preferential Interaction Type of Excipient and Surface Aromatic Hydrophobicity of Protein. Pharm. Res. 2017, 34 (7), 1378–1390.

    OpenUrlPubMed
77. 77.↵
    1. Cao X.,
    2. Fesinmeyer R. M.,
    3. Pierini C. J.,
    4. Siska C. C.,
    5. Litowski J. R.,
    6. Brych S.,
    7. Wen Z.-Q.,
    8. Kleemann G. R.

    Free Fatty Acid Particles in Protein Formulations, Part 1: Microspectroscopic Identification. J. Pharm. Sci. 2015, 104 (2), 433–446.

    OpenUrlPubMed
78. 78.↵
    1. Kerwin B. A.

    Polysorbates 20 and 80 Used in the Formulation of Protein Biotherapeutics: Structure and Degradation Pathways. J. Pharm. Sci. 2008, 97 (8), 2924–2935.

    OpenUrlCrossRefPubMed
79. 79.↵
    1. Katakam M.,
    2. Bell L. N.,
    3. Banga A. K.

    Effect of Surfactants on the Physical Stability of Recombinant Human Growth Hormone. J. Pharm. Sci. 1995, 84 (6), 713–716.

    OpenUrlCrossRefPubMedWeb of Science
80. 80.↵
    1. Kishore R. S. K.,
    2. Kiese S.,
    3. Fischer S.,
    4. Pappenberger A.,
    5. Grauschopf U.,
    6. Mahler H.-C.

    The Degradation of Polysorbates 20 and 80 and Its Potential Impact on the Stability of Biotherapeutics. Pharm. Res. 2011, 28 (5), 1194–1210.

    OpenUrlPubMed
81. 81.↵
    1. Maa Y.-F.,
    2. Hsu C. C.

    Investigation on Fouling Mechanisms for Recombinant Human Growth Hormone Sterile Filtration. J. Pharm. Sci. 1998, 87 (7), 808–812.

    OpenUrlCrossRefPubMed
82. 82.↵
    1. Carpenter J. F.,
    2. Manning M. C.

    1. Randolph T. W.,
    2. Jones L. S.

    Surfactant-Protein Interactions. In Rational Design of Stable Protein Formulations: Theory and Practice; Carpenter J. F., Manning M. C., Eds.; Springer: New York, 2002; pp 159–175.
83. 83.↵
    1. Himanen J.-P.,
    2. Sarvas M.,
    3. Helander I. M.

    Assessment of Non-Protein Impurities in Potential Vaccine Proteins Produced by Bacillus subtilis. Vaccine 1993, 11 (9), 970–973.

    OpenUrlCrossRefPubMed
84. 84.↵
    1. Johnston A.,
    2. Uren E.,
    3. Johnstone D.,
    4. Wu J.

    Low pH, Caprylate Incubation as a Second Viral Inactivation Step in the Manufacture of Albumin: Parametric and Validation Studies. Biologicals 2003, 31 (3), 213–221.

    OpenUrlPubMed
85. 85.↵
    1. Tong H.-F.,
    2. Lin D.-Q.,
    3. Gao D.,
    4. Yuan X.-M.,
    5. Yao S.-J.

    Caprylate as the Albumin-Selective Modifier to Improve IgG Purification with Hydrophobic Charge-Induction Chromatography. J. Chromatogr. A 2013, 1285, 88–96.

    OpenUrlPubMed